CA3109983A1 - Spd-1 variant - fc fusion proteins - Google Patents

Spd-1 variant - fc fusion proteins Download PDF

Info

Publication number
CA3109983A1
CA3109983A1 CA3109983A CA3109983A CA3109983A1 CA 3109983 A1 CA3109983 A1 CA 3109983A1 CA 3109983 A CA3109983 A CA 3109983A CA 3109983 A CA3109983 A CA 3109983A CA 3109983 A1 CA3109983 A1 CA 3109983A1
Authority
CA
Canada
Prior art keywords
spd
variant
domain
seq
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3109983A
Other languages
English (en)
French (fr)
Inventor
Amato J. Giaccia
Todd A. AGUILERA
Mihalis S. Kariolis
Yu MIAO
Kaushik THAKKAR
Xin Eric ZHANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akso Biopharmaceutical Inc
Leland Stanford Junior University
Original Assignee
Akso Biopharmaceutical Inc
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akso Biopharmaceutical Inc, Leland Stanford Junior University filed Critical Akso Biopharmaceutical Inc
Publication of CA3109983A1 publication Critical patent/CA3109983A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3109983A 2018-09-14 2019-09-12 Spd-1 variant - fc fusion proteins Pending CA3109983A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862731488P 2018-09-14 2018-09-14
US62/731,488 2018-09-14
US201962888320P 2019-08-16 2019-08-16
US62/888,320 2019-08-16
PCT/US2019/050742 WO2020056085A1 (en) 2018-09-14 2019-09-12 Spd-1 variant - fc fusion proteins

Publications (1)

Publication Number Publication Date
CA3109983A1 true CA3109983A1 (en) 2020-03-19

Family

ID=68211179

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3109983A Pending CA3109983A1 (en) 2018-09-14 2019-09-12 Spd-1 variant - fc fusion proteins

Country Status (11)

Country Link
US (2) US11498955B2 (https=)
EP (1) EP3850003A1 (https=)
JP (1) JP2021535761A (https=)
KR (1) KR20210058902A (https=)
CN (1) CN112969710A (https=)
AU (1) AU2019338416A1 (https=)
CA (1) CA3109983A1 (https=)
NZ (1) NZ774126A (https=)
SG (1) SG11202101904UA (https=)
TW (2) TWI815964B (https=)
WO (1) WO2020056085A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016164428A1 (en) * 2015-04-06 2016-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor-based antagonists of the programmed cell death 1 (pd-1) pathway
EP3991741A1 (en) * 2020-11-02 2022-05-04 Klinikum rechts der Isar der Technischen Universität München An immune checkpoint-modulating vsv-ndv hybrid virus for oncolytic virus immonotherapy of cancer
EP4243852A4 (en) * 2020-11-13 2024-12-11 Ludwig Institute for Cancer Research Ltd PD-1 DECOY VARIANTS FOR IMMUNOTHERAPY
WO2022137186A1 (en) 2020-12-23 2022-06-30 Crispr Therapeutics Ag Cancer treatment using cd38 inhibitor and/or lenalidomide and t-cells expressing a chimeric antigen receptor
EP4274852A4 (en) * 2021-01-11 2025-02-26 Eutilex Co., Ltd. BISPECIFIC EPITOP-BINDING PROTEIN WITH ANTI-4-1BB ANTIBODY AND PD-1 PROTEIN OR FRAGMENTS THEREOF AND USE THEREOF
EP4288080A1 (en) * 2021-02-04 2023-12-13 Helsingin Yliopisto A cross-hybrid fc-fusion polypeptide targeting pd-l1 and methods and uses related thereto
US20240141014A1 (en) * 2021-03-03 2024-05-02 Shattuck Labs, Inc. Mutant pd-1 extracellular domains
WO2022238962A1 (en) 2021-05-12 2022-11-17 Crispr Therapeutics Ag Genetically engineered immune cells targeting cd70 for use in treating hematopoietic malignancies
US20250115657A1 (en) * 2021-05-28 2025-04-10 Akso Biopharmaceutical, Inc. Bispecific FC Fusion Proteins with sPD-1 and IL-15
WO2023048518A1 (ko) * 2021-09-24 2023-03-30 바이오엔시스템스 주식회사 Pd-1 및 il-15를 포함하는 융합단백질 이량체 및 이의 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2693504A1 (en) * 2007-08-03 2009-02-12 Eli Lilly And Company Treatment for obesity
CN103261217B (zh) * 2010-11-11 2017-04-26 港大科桥有限公司 可溶性 pd‑1变体、融合构建体及其用途
US20150368316A1 (en) 2013-02-07 2015-12-24 Albert Einstein College Of Medicine Of Yeshiva University A selective high-affinity immune stimulatory reagent and uses thereof
US9546206B2 (en) * 2014-08-08 2017-01-17 The Board Of Trustees Of The Leland Stanford Junior University High affinity PD-1 agents and methods of use
WO2016023001A1 (en) * 2014-08-08 2016-02-11 The Board Of Trustees Of The Leland Stanford Junior University Multispecific high affinity pd-1 agents and methods of use
WO2016164428A1 (en) 2015-04-06 2016-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor-based antagonists of the programmed cell death 1 (pd-1) pathway
EP3303383A1 (en) * 2015-06-05 2018-04-11 iBio, Inc. Endostatin fragments and variants for use in treating fibrosis
PL3368572T3 (pl) * 2015-10-02 2022-09-12 Symphogen A/S Przeciwciała anty-PD-1 oraz kompozycje
WO2017123548A1 (en) 2016-01-14 2017-07-20 Seattle Children's Hospital (dba Seattle Children's Research Institute) Tumor-specific ifna secretion by car t-cells to reprogram the solid tumor microenvironment
WO2018104473A1 (en) * 2016-12-07 2018-06-14 Oslo Universitetssykehus Hf Compositions and methods for cell therapy
US12065476B2 (en) * 2018-06-15 2024-08-20 Alpine Immune Sciences, Inc. PD-1 variant immunomodulatory proteins and uses thereof

Also Published As

Publication number Publication date
TW202023604A (zh) 2020-07-01
NZ774126A (en) 2023-05-26
SG11202101904UA (en) 2021-04-29
US20230131056A1 (en) 2023-04-27
AU2019338416A1 (en) 2021-04-29
US11498955B2 (en) 2022-11-15
TWI815964B (zh) 2023-09-21
JP2021535761A (ja) 2021-12-23
WO2020056085A1 (en) 2020-03-19
TW202348622A (zh) 2023-12-16
EP3850003A1 (en) 2021-07-21
US20200181231A1 (en) 2020-06-11
KR20210058902A (ko) 2021-05-24
CN112969710A (zh) 2021-06-15

Similar Documents

Publication Publication Date Title
US20230131056A1 (en) sPD-1 VARIANT – FC FUSION PROTEINS
US20230055445A1 (en) Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
JP7273453B2 (ja) ＩＬ－１５／ＩＬ－１５ＲアルファＦｃ融合タンパク質およびＰＤ－１抗体の断片を含む二重特異性ヘテロ二量体融合タンパク質
JP7809680B2 (ja) 癌処置のための多重特異性結合タンパク質
JP2024153643A (ja) Ｉｌ－１５／ｉｌ－１５ｒａヘテロ二量体ｆｃ融合タンパク質およびその使用
KR20210010862A (ko) IL-15/IL-15Rα Fc-융합 단백질 및 PD-1 항원 결합 도메인을 함유하는 PD-1 표적화 이종이량체 융합 단백질 및 이의 용도
US20250215081A1 (en) Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
US20220411533A1 (en) Novel Tri-specific Binding Molecules
RU2785993C2 (ru) ГИБРИДНЫЕ БЕЛКИ ВАРИАНТА sPD-1—FC
CN117715940A (zh) 抗trem-1抗体
NZ796397A (en) sPD-1 variant - Fc fusion proteins
HK40053326A (en) Spd-1 variant - fc fusion proteins
RU2827796C2 (ru) Гетеродимерные слитые белки ИЛ-15/ИЛ-15Рα - Fc и их применение

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220926

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20240807

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5